Recent reports of immunoassays specify the sensitive detection of differential p-tau231, 181, and 217 proteins in the CSF of patients with AD, revealing reliable p-tau biomarkers for AD diagnosis [1,3]. This evidence concerns the gene MAPT and Alzheimer disease.